The study involved data from 1,461 high-risk individuals enrolled in CAPS5 between 2014 and 2021 and from a total of 1,731 high-risk individuals enrolled in the total CAPS cohort, comprising the CAPS1–5 studies; the CAPS1–4 studies were single-institution studies initiated at Johns Hopkins in 1998. High-risk was defined as lifetime risk ≥ 5% based on the number of affected first-degree relatives with pancreatic cancer or identification of a pathogenic germline variant in a pancreatic cancer susceptibility gene. Participants were recommended to undergo (typically annual) pancreas imaging surveillance with magnetic resonance imaging and endoscopic ultrasound. The primary outcome measure was stage distribution among participants developing pancreatic ductal adenocarcinoma. Read more . . .
As reported in the Journal of Clinical Oncology by Dbouk et al, in the multicenter Cancer of Pancreas Screening-5 (CAPS5) study and in the total CAPS cohort (CAPS1–5 studies), cases of pancreatic ductal adenocarcinoma among enrolled high-risk individuals that were screen-detected during surveillance were diagnosed at earlier stages vs those diagnosed outside of surveillance. Diagnosis within the surveillance period was associated with improved survival outcomes.